Halozyme Therapeutics Q3 2024 Adj. EPS $1.27 Beats $0.98 Estimate, Sales $290.084M Beat $251.059M Estimate
Portfolio Pulse from Benzinga Newsdesk
Halozyme Therapeutics reported Q3 2024 earnings per share of $1.27, surpassing the analyst estimate of $0.98. The company's sales reached $290.084 million, exceeding the expected $251.059 million and marking a 34.28% increase from the previous year.
October 31, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Halozyme Therapeutics reported strong Q3 2024 results, with EPS of $1.27 beating estimates by 29.59% and sales of $290.084M exceeding expectations by 15.54%.
The significant beat on both EPS and sales estimates, along with a substantial year-over-year sales increase, suggests positive investor sentiment and potential upward movement in HALO's stock price.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100